Related Experiment Video

Updated: Aug 20, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Treatment of recurrent or metastatic renal cell carcinoma

Riyaz N H Shah1, Tanya Ahmad, Tim G Eisen

  • 1Department of Medical Oncology, The Royal Marsden Hospital, Sutton SM2 5PT, UK. riyaz.shah@rmh.nhs.uk

Expert Review of Anticancer Therapy
|December 21, 2004
PubMed

Insights

Recurrent renal cell carcinoma management is complex, with limited options for metastatic disease. Novel drug development shows promise for improved patient outcomes in this challenging cancer.

Area of Science:

  • Oncology
  • Medical Research
  • Drug Development

Background:

  • Recurrent renal cell carcinoma (RCC) presents significant management challenges.
  • Current treatment options for metastatic RCC offer modest benefits.
  • RCC serves as a critical model for developing new therapeutic agents.

Purpose of the Study:

  • To review the current landscape of recurrent renal cell carcinoma management.
  • To highlight the progress and preliminary findings in novel drug development for metastatic RCC.
  • To discuss the collaborative efforts required among specialists for effective RCC treatment.

Main Methods:

  • Review of existing literature on recurrent renal cell carcinoma.
  • Analysis of preliminary data from novel drug development programs targeting RCC.
  • Synthesis of information on multidisciplinary approaches in RCC management.

Main Results:

  • Emerging data indicates promising preliminary results from novel agents.
  • The development of new therapeutic strategies is showing encouraging signs.
  • Collaboration between surgical, radiation, and medical oncology is crucial.

Conclusions:

  • Novel drug development is yielding promising preliminary data for recurrent RCC.
  • Advances in treatment options are anticipated for metastatic renal cell carcinoma.
  • Multidisciplinary collaboration is essential for optimizing patient care in recurrent RCC.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...